Amgen Inc. $AMGN Shares Sold by Swiss Life Asset Management Ltd

Swiss Life Asset Management Ltd reduced its position in Amgen Inc. (NASDAQ:AMGN) by 27.0% in the 4th quarter, Holdings Channel reports. The firm owned 198,126 shares of the medical research company’s stock after selling 73,214 shares during the quarter. Swiss Life Asset Management Ltd’s holdings in Amgen were worth $64,849,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Anfield Capital Management LLC raised its stake in Amgen by 1,000.0% in the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 70 shares during the last quarter. Dogwood Wealth Management LLC raised its stake in Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock valued at $25,000 after purchasing an additional 55 shares during the last quarter. Board of the Pension Protection Fund acquired a new position in Amgen in the 4th quarter valued at $26,000. Manning & Napier Advisors LLC raised its stake in Amgen by 49.2% in the 4th quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock valued at $32,000 after purchasing an additional 32 shares during the last quarter. Finally, Olistico Wealth LLC acquired a new position in Amgen in the 4th quarter valued at $33,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently commented on AMGN. Cantor Fitzgerald reissued a “neutral” rating and issued a $350.00 price objective on shares of Amgen in a research note on Wednesday, April 8th. Argus raised their target price on Amgen from $360.00 to $400.00 and gave the stock a “buy” rating in a research note on Friday, February 6th. Wall Street Zen downgraded Amgen from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Erste Group Bank reaffirmed a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. Finally, Canaccord Genuity Group started coverage on Amgen in a research note on Monday, April 20th. They issued a “hold” rating and a $366.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $357.12.

Amgen Price Performance

Shares of AMGN opened at $331.70 on Monday. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a market capitalization of $179.01 billion, a PE ratio of 23.08, a price-to-earnings-growth ratio of 3.33 and a beta of 0.44. The stock has a fifty day simple moving average of $355.12 and a two-hundred day simple moving average of $341.81. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65.

Amgen (NASDAQ:AMGN) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same period last year, the company earned $4.90 EPS. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.36 EPS for the current year.

Amgen Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. Amgen’s dividend payout ratio is currently 70.15%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction on Monday, May 4th. The stock was sold at an average price of $323.73, for a total transaction of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This represents a 15.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.